| Publications [#63295] of Mark W. Dewhirst
Papers Published
- Laskowitz, K.T. and Elion, G.B. and Dewhirst, M.W. and Griffith, O.W. and Savina, P.M. and Blum, M.R. and Prescott, D.M. and Bigner, D.D. and Friedman, H.S., Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft,
Radiat. Res. (USA), vol. 129 no. 2
(1992),
pp. 218 - 23
(last updated on 2007/04/14)
Abstract: The effects of regional hyperthermia (42°C for 70 min) on the antitumor activity of melphalan were examined in athymic mice bearing melphalan-resistant human rhabdomyosarcoma (TE-671 MR) xenografts growing in the right hind limb, and results were compared with similar studies of melphalan-sensitive (TE-671) parent xenografts. Melphalan alone at a dose of 36 mg/m2 (0.5 of the 10% lethal dose) produced growth delays of 4.1 to 10.2 days in TE-671 MR xenografts and 21.8 to 28.7 days in TE-671, respectively. Hyperthermia alone produced growth delays of 0.9 days in TE-671 MR xenografts and 0.8 days in TE-671. Combination therapy with melphalan and hyperthermia produced growth delays of 7.2 to 13.3 days in TE-671 MR xenografts and 34.3 to 42.8 days in TE-671, respectively, representing a mean thermal enhancement ratio of 1.7 in TE-671 MR and 1.5 in TE-671. Combination therapy with melphalan plus regional hyperthermia offers promise for treatment of melphalan-resistant neoplasms
Keywords: biothermics;muscle;
|